Tenaya Therapeutics (TNYA) 10-Q2023 Q1 Quarterly report

Filed: 10 May 23, 4:35pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accessed, accessible, accretion, acetylation, adjourned, ambiguity, background, Becerra, biodistribution, biomarker, blood, Catalyst, Cir, circulating, clarify, component, copy, Cowen, Deepak, deteriorate, differentiated, Dr, EC, editing, EEA, England, entirety, Fast, GMP, halt, harder, healthy, injection, investor, IRA, Ireland, judgment, lab, length, longstanding, machine, MAD, metabolism, ministerial, modular, Morgan, mouse, MyClimb, noninterventional, Northern, objective, overallotment, paper, pathogenic, pathophysiology, PD, phenotypic, Piper, proven, proxy, quorum, relax, retrospective, reverse, rhythm, SAD, Sandler, Scotland, screening, serotype, SI, smooth, Srivastava, Stanley, stiffening, suite, suited, thought, tubulin, tying, underwriting, underwritten, Unified, virtue, warrant

Removed: accomplishing, activation, actively, age, agreed, Ali, allegation, alleging, alter, alternate, Alternatively, analogizing, analyzing, announced, assistance, assuming, attack, augment, authorizing, bioresearch, blocking, Brexit, built, calculating, CDPA, certainty, clearance, close, codified, collecting, Colorado, commandeered, Commissioner, committed, commonplace, communication, compel, connected, constitutional, constitutionality, construction, contact, contracting, controlled, corrective, counsel, counteract, counterclaim, CPA, CPRA, creating, creation, CRPA, culture, deceptive, dedicated, defendant, defended, demonstrating, demonstration, designing, die, diligently, disadvantage, disapproval, disclosing, discontinued, dismissing, dispensing, distancing, divergent, DOJ, dosage, double, downturn, DWORF, enabled, enact, encountered, ending, epidemic, equitable, establishment, existed, exited, expanded, exploited, explored, Faraz, FIH, forward, gaining, geographical, globally, greatest, guide, heightening, HFrEF, hired, historically, hypertrophy, improving, incurrence, indefinitely, injunction, inspected, integrate, intentionally, internalize, intervening, intra, invent, invested, invoiced, involvement, issuing, jeopardizing, lawful, lawfully, learned, letter, line, Luxturna, medication, medium, methodology, minimization, misleading, misrepresentative, modest, morbidity, mortality, motivating, mutually, nonexclusive, Obama, official, onsite, outbreak, overexpressing, owed, parallel, patentability, patented, patenting, PCT, people, peptide, persuade, pharmacology, Plant, post, precluding, prioritized, procurement, prohibiting, prosecuted, provisional, provoke, provoked, pursued, qualifying, rating, reallocation, recommended, reconsider, reexamining, referencing, reliable, relief, remind, remotely, represent, resume, resumed, revoke, Roche, ruling, safest, scale, scaled, sensitive, sequester, shared, shipment, shorten, simplify, Simplifying, Spark, stability, statewide, step, substantive, sufficiency, surveillance, switched, systemic, Taxpayer, temporary, transparent, transport, unilaterally, unmet, unnecessary, view, Virginia, waiver, withheld, Zolgensma

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TNYA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Faraz Ali, M.B.A., certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, (1) the Quarterly Report on Form 10-Q of Tenaya Therapeutics, Inc. (the “Company”) for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/s/ Faraz Ali, M.B.A.
		Faraz Ali, M.B.A.
		Chief Executive Officer and Director (Principal Executive Officer)
		Date: May 10, 2023

I, Leone D. Patterson, M.B.A., certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, (1) the Quarterly Report on Form 10-Q of Tenaya Therapeutics, Inc. (the “Company”) for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/s/ Leone D. Patterson, M.B.A.
		Leone D. Patterson, M.B.A.
		Chief Financial and Business Officer (Principal Financial and Accounting Officer)
		Date: May 10, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.